רווח למניה בשנים עשר החודשים האחרונים: Kairos Pharma Limited (KAPA)

Kairos Pharma Ltd (KAPA) revenues are based on future insurance payouts and partnerships with clinics. Targeted therapy developments create growth potential, despite speculative pipeline risks. The current EPS TTM illustrates the dynamics of this interaction, where -1.45 shows the current value of the metric. This results in the status of a promising brand with an impeccable scientific reputation in treating resistant forms of cancer.
פילוחי נתונים אנליטיים מרוכזים עבור Kairos Pharma Inc (KAPA)

The metric is calculated by dividing the total annual net income by the total number of shares outstanding. This metric determines the actual income share per security, excluding the impact of equity dilution. For Kairos Pharma Ltd (KAPA), this parameter reflects the efficiency of monetizing unique methods for combating resistant cancer. Monopoly pricing power over scarce treatments directly influences the dynamics of this value. By analyzing this 12-month net income per share chart, an investor can promptly identify stagnation or growth in the business's fundamental value.